Scout | Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required)

This opportunity is no longer accepting applications.

grant

Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required)

This grant opportunity aims to support a multi-center consortium to form a clinical trials network focused on older adults with chronic pain conditions. The funding mechanism is phased into UG3 and UH3 stages. The UG3 phase, lasting up to 2 years, involves initial studies in healthy older adults to assess the safety and effects of psychedelic agents, which include substances like psilocybin, L…

Source

Agency: National Institutes of Health

Program: SBIR

Dates

Application Window Closes: October 10, 2024

Opportunity Released: April 24, 2024

Open for Submission: April 24, 2024

Submission Deadline: October 10, 2024

Keywords

Psychedelic-Assisted Therapy

Chronic Pain

Older Adults

Clinical Trials

Safety Studies

Efficacy Studies

Multi-Center Consortium

5-HT2 Agonists

Psilocybin

Pharmacokinetics

Pharmacodynamics

UG3/UH3 Mechanism.

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers